Graft-versus-host disease
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Axatilimab (SNDX-6352) + Jakafi® (ruxolitinib) in Graft-versus-host disease . The expected timing is based on the latest available company guidance and may change.
Collab w/ Incyte, initiate a trial in mid-2024. 11/03/25:- Ph2 Niktimvo+ruxolitinib trial in newly diagnosed chronic GVHD patients ≥12 years is ongoing; ASH 2025 abstracts planned. 02/26/26:- Ph2 Niktimvo+ruxolitinib trial NCT06388564 shows tolerability in newly diagnosed chronic GVHD; BOS analyses presented. 04/30/26:- Ph2 Niktimvo+ruxolitinib frontline chronic GVHD topline data anticipated in Q4 2026. 08/04/26:- Ph2 axatilimab plus ruxolitinib topline data reiterated for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.